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Introduction:The advent of human genome project has lead to genetic tests that identify
high-risk states for certain cancers. Many are privately marketed on the Internet. Despite
the availability of tests, limited data has evaluated factors that lead to test uptake.The aim
of the present study was to explore the attitudes of a cohort of new mothers toward uptake
of a genetic cancer test with a 50% predictive value of cancer.
Methods:A cross-sectional survey was undertaken.The project targeted women who had
recently given birth at an Australian tertiary referral hospital. Women were asked about
a theoretical blood test that detected an increased risk for the development of cancer.
Attitudes and knowledge questionnaires were completed.
Results: Of 232 consecutive women approached, 32 declined, giving a response rate of
86.2%. Only 63 (31.5%) women stated they would have the test. Absence of religious
belief, higher level of education, better knowledge of terms used in genetics, an absence
of concern over emotional, employment, and insurance discrimination, and previous accep-
tance of Down syndrome screening in pregnancy were each associated with significantly
higher rate of test uptake in univariate analysis (all p<0.03). In multivariate analysis, a lack of
concern over discrimination and a history of having accepted Down syndrome screening in
the previous pregnancy remained significantly associated with test uptake (all p<0.0001).
Conclusion: Concern over discrimination and having made a prior decision to have genetic
testing were the principal factors associated with decision-making.
Keywords: breast cancer, genetic cancer screening, pregnancy, discrimination, ethics, education
INTRODUCTION
The advent of human genome project has lead to genetic tests that
identify high-risk states for certain cancers. Commercial compa-
nies now market the availability of these tests on the Internet.
However consumer agencies and medical staff are concerned
this will lead to medicine for the rich and inadequate pre-test
counseling (1–5).
Whilst healthcare providers offer recommendations and guid-
ance about genetic cancer testing to screen appropriate patient
groups, ultimately, the onus is left on patients and their families to
decide whether or not to uptake testing.
The published literature has identified several factors that influ-
ence this decision. One study compared the impact of demo-
graphic variables, medical history, and psychological factors on
uptake of genetic testing for hereditary colorectal cancer (1). An
association was found between increased test uptake and those
candidates with increased risk perception, greater perceived confi-
dence in their ability to cope with unfavorable genetic information,
more frequent cancer thoughts, and those having undergone pre-
vious screening (colonoscopy examination) (1). Similar findings
have been reported in studies investigating the association between
psychological factors and cancer screening behaviors (2–6).
Other documented motivating factors influencing decisions to
uptake genetic testing include a desire to seek information on per-
sonal and family (especially offspring’s) risk of disease, to detect
cancer at an early stage, and to contribute to research in the field of
genetic testing (7). Conversely, concerns over loss of health insur-
ance and the potential psychological consequences of testing were
quoted in other studies as reasons for declining test uptake (8, 9).
Limited data has evaluated the impact of knowledge of genetics
and attitudes toward genetic-based discrimination in combination
with actual testing behaviors.
The aim of this study was to explore the relative impact of
demographic variables, level of knowledge, attitudes on poten-
tial discrimination, and previous genetic testing behavior on a
woman’s decision as to whether she would accept or decline a
genetic cancer test that could predict the onset of cancer within
the next 5 years.
MATERIALS AND METHODS
A cross-sectional survey was undertaken. The study had the
approval of the Institutional Human Research and Ethics Com-
mittee. Individual informed written consent was obtained from
each participant. The project targeted women who had recently
www.frontiersin.org January 2014 | Volume 3 | Article 325 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quinlivan et al. Predicting genetic cancer test uptake
given birth at an Australian tertiary referral hospital. Non-English
speaking women were specifically included in the study by utiliz-
ing qualified medical interpreters and research assistants who were
fluent in several languages.
The recruitment of subjects took place in the postnatal wards
of the hospital. All participants had previously had to make a
personal decision about accepting or declining genetic testing in
relation to their pregnancy in respect to Down syndrome screen-
ing or diagnostic testing, and on behalf of their baby with respect
to the newborn screen.
QUESTIONNAIRE DESIGN
Women were asked a specific question about a theoretical blood
test that could detect an increased risk for the development of
cancer. The question was piloted on a focus group before being
finalized. The starting point of the question assumed a woman
had undergone a pedigree analysis. The woman was then asked
the question:
“Imagine that there was a blood test that could tell you that
there is a 50% chance (that is 1 in 2 chance) that you will get a
specific cancer within 5 years time. Would you take the test?”
An attitudes questionnaire was then completed that covered
women’s attitudes toward potential discrimination in relation to
genetic testing. Women were asked whether they thought a positive
genetic result would be associated with
a. an effect on emotional and psychological development
b. an effect on obtaining insurance
c. an effect on employment.
Participants also completed a knowledge questionnaire that was
designed to evaluate the knowledge of women in respect to key
terms used in counseling for genetic testing. The details of this
questionnaire have been previously described (10). The score for
the knowledge questionnaire ranged from a minimum of 0 to a
maximum of 15 with median score of 4.
The final part of the questionnaire covered demographic fac-
tors, family history of genetic disease (apart from cancer), and
cancer. A readability formula, the SMOG index, was applied to the
wording of the questionnaire (11). This ensured that the readabil-
ity of the questions was in accordance with the published literacy
figures for the Australian population. The resulting SMOG index
of the questionnaire was 8. This meant that important concepts
in the questionnaire would be understood by 90% of readers who
had completed grade 8.
SAMPLE SIZE AND STATISTICAL ANALYSIS
The primary hypothesis was that fear of discrimination may deter
women from seeking out tests that might detect an increased risk of
cancer. It was predicted that a fear of discrimination might reduce
test uptake from 50 to 25%. Given a two-sided α error of 0.05
and β error of 0.80, 65 women would be required as a minimum
in each arm of the study. We predicted that 35% of women may
worry about discrimination, and therefore predicted that at least
186 women would need to be enrolled in the study. We therefore
aimed for a population target of 200.
Data collected were analyzed using Epi Info, Centre for Dis-
ease Control. Demographics of the study cohort were compared
against the broader demographics of the Victorian maternal pop-
ulation in respect to age, marital status, primary language, religion,
and parity in order to assess the generalizability of findings in the
study cohort to the wider obstetric population (12, 13).
Descriptive statistics were obtained on individual questions.
Discrete variables are reported as N (%) and were compared using
Chi square or Fishers Exact test according to cell size. Continuous
variables are reported as mean (standard deviation) or median
(interquartile range) and were assessed using Students t -test or
Mann–Whitney U test according to distribution. Results were also
compared against the women’s previous decision in relation to
Down syndrome testing.
Multivariate analyses of variance was performed with the model
including factors found to be significant on univariate analysis at
a p-value <0.1 The dependent variable was test uptake. A p-value
of 0.05 was considered significant.
RESULTS
Of 232 consecutive women approached, 32 declined, giving a
response rate of 86.2%. The commonest reasons for the mother
declining participation were that they were too busy with their
newborn babies or tired.
The demographics of the cohort are summarized in Table 1
which compares the demographic details of the study cohort and
to data available for the State of Victoria Australia. Key demo-
graphics were similar. However proportionally more women with
a religious belief stated it was Islam compared to the breakdown
of type of religion in population data for the State, although the
total proportion of women with any religious belief was similar.
As there were no differences by type of religion for any variable,
data on religious belief were pooled for analysis.
Only 63 (31.5%) of women stated that they would be prepared
to have a blood test that might tell them that they had a 50% risk
of acquiring a cancer in the next 5 years.
Table 2 summarizes the impact of demographic variables on
the decision for test uptake. Women without a religious belief
were significantly more likely to consider test uptake compared
to those without (44 vs. 27%, p= 0.02). Level of education also
significantly influenced the decision for test uptake (p= 0.02). Of
note, the variables of family history of genetic disease (except can-
cer) and family history of cancer did not significantly impact upon
the decision to have the theoretical test.
Table 3 summarizes the influence of knowledge of genetic ter-
minology, attitudes, and previous decision making in respect to
Down syndrome testing on the decision to consider testing for can-
cer risk. Women who stated they would have testing to determine
if they were at 50% risk of developing cancer in the next 5 years had
significantly higher levels of knowledge of terms used in genetic
counseling (score 5 vs. 3, p= 0.03). Women who were concerned
about possible emotional, employment, or insurance disadvan-
tage as a result of being a carrier were significantly less likely to
undertake testing (all p< 0.0001). Women who had elected to have
screening or diagnostic testing for Down syndrome in their pre-
ceding pregnancy were significantly more likely to agree to cancer
testing (55 vs. 3%, p< 00001).
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Table 1 | Demographics.
Variables Study
population
Victorian
data
Age in years 29.1 (5.6) 29.7
Mean (SD)
Marital status
Married N (%) 146 (73%) 75.3%
English as the first language N (%)
Yes 117 (58.5)
No 83 (41.5)
Ethnic background N (%)
Caucasian 86 (43)
Mixed race 64 (32%)
Asian 28 (14)
ATSI 14 (7%)
Pacific islander 5 (2.5%)
African 3 (1.5%)
Religious belief
Yes N (%) 149 (74.5%) 74.4%
Level of education N (%)
No school or 10 school only 8 (4%)
Attended part of 20 secondary school 50 (25%)
Completed secondary school 142 (71%)
Income of family before tax N (%)
<$20,000 36 (18%)
$20,000–$30,000 32 (16%)
$30,000–$40,000 43 (21.5%)
>$40,000 67 (33.5%)
Not disclosed 22 (11%)
Parity N (%)
1 86 (43%) 41.7%
2 or more 113 (56.5%)
Did not answer 1 (0.5)
The multivariate analysis included all variables significant at a
univariate level of p< 0.1. A belief that a positive result would be
associated with discrimination and a history of having accepted
screening for Down syndrome in the previous pregnancy remained
significantly associated with the decision on test uptake (all
p< 0.0001) (Tables 2 and 3).
DISCUSSION
Various studies over the past couple of decades have investigated
the factors impacting upon decisions to undertake genetic testing
predictive for cancer as well as other conditions, including sickle
cell disease (14), colon cancer (1), bipolar disorder (15). This study
is unique, however, in that the focus was shifted from considera-
tions pertaining to the nature of the actual medical condition
tested for, to a holistic exploration of the relative impact of mul-
tiple psychosocial factors, alongside demographic and behavioral
variables, on a woman’s decision to accept or decline a hypothetical
genetic test that could predict the onset of cancer within the next
5 years. These factors included family history of genetic disease,
family history of cancer, knowledge about terms used in genetic
testing counseling, actual behavior in relation to a decision to
accept or decline genetic testing of their fetus in an immediate
prior pregnancy and attitudes toward potential discrimination.
Our study is also unique for the target population cohort studied.
A higher tendency toward test uptake was found in our post-
natal women cohort who did not have concerns in relation to
emotional, employment, or insurance discrimination and who had
better knowledge of terms used in genetic counseling. Moreover,
and of greater significance perhaps, was the multivariate analy-
sis that found an independent adverse association between the
decision on test uptake and a belief that a positive result would
be associated with discrimination; and a favorable association in
women with a prior history of having previously accepted screen-
ing or diagnostic testing for Down syndrome in their preceding
pregnancy. These findings highlight a potentially pertinent limi-
tation to the advent and use of genetic testing to screen for certain
disease states; that is, cautious acceptance of these proposed tests
and hesitancy toward uptake by a general public who are fearful of
the potential professional and personal implications that the test
results may yield. In essence, this represents hypothetical fear of
genetic-based discrimination.
GENETIC-BASED DISCRIMINATION
Many definitions of genetic-based discrimination have been
offered by sociocultural and scholarly institutions in response to
the increasing availability of genetic testing over the past three
decades. Debate in this field has focused on the potential implica-
tions of genetic-based discrimination, including risk of actual or
feared psychological/emotional disadvantage, as well as exclusion
from access to employment, insurance and healthcare (16).
EMPLOYMENT AND INSURANCE DISCRIMINATION
One debate raised concern about the potential access and use
by employers of this source of health information as a selection
criteria in the context of recruitment and workplace relations.
Genetically based employment discrimination is the term coined
to describe “the denial of workplace rights, privileges, or opportu-
nities on the basis of information obtained from genetically based
diagnostic and prognostic tests” (17). Fears of discrimination have
realized in the United States where nearly two-thirds of the 1000
respondents in a survey conducted by the National Center for
Genome Resources indicated they would refuse genetic testing if
results were made available to employers and insurance companies,
and 85% objected to employers accessing this information (18). In
the Australian context, a report prepared in May 2003, and recently
modified in 2012, by the joint efforts of the Australian Law Reform
Commission (ALRC) and the Australian Health Ethics Commit-
tee (AHEC) of the National Health and Medical Research Council
(NHMRC) offered guidelines about how to deal with the ethical,
legal, and social implications of genetic information in Australia
(19). The report contains specific regulations pertaining to the
legalities of genetic determinism and use of genetic testing and
information in employment.
The prevalence of actual cases (reported and unreported) of
genetic-based employment discrimination in Australia remains
largely undefined. However, several cases were identified in a 2001
study of genetic discrimination in Australia. Case were docu-
mented of employer-requested pre-employment genetic testing, as
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Table 2 | Impact of demographic factors on decision on test uptake.
Variables Accept test (N =63) Decline test (N =137) p-Value (univariate) p-Valuec (multivariate)
Demographics
Age mean (SD) 28.9 (5.2) 29.2 (5.8) 0.77
Marital status
Married 50 (34%) 96 (66%) 0.19
Defacto 11 (30%) 26 (70%)
Single 2 (1%) 14 (88%)
Missing data 0 1
English first language
Yes 33 (28%) 84 (72%) 0.23
No 30 (36%) 53 (64%)
Ethnic background
Caucasian 33 (38%) 53 (62%) 0.18
Asian 8 (40%) 20 (60%)
Othera 22 (24%) 64 (76%)
Religion
No religion 22 (44%) 28 (56%) 0.02 0.17
Religion 40 (27%) 109 (73%)
Subtype of religion
Christian 23 (29%) 56 (71%)
Islam 14 (32%) 30 (68%)
Otherb 3 (12%) 23 (88%)
Missing data n=1 1 0
Education
No school or 10 school only 0 (0%) 8 (100%) 0.02 0.13
Attended part of 20 secondary school 11 (22%) 39 (78%)
Completed secondary school 52 (37%) 90 (63%)
Income
<$20,000 7 (19%) 29 (81%) 0.09 0.46
$20,000–$30,000 12 (37%) 20 (63%)
$30,000–$40,000 20 (47%) 23 (53%)
>$40,000 24 (36%) 43 (64%)
Missing data 0 22
Parity
1 27 (31%) 59 (69%) 0.94
2 or more 36 (32%) 77 (68%)
Missing data 0 1
Family history of genetic disease (except cancer)
Yes 8 (36%) 14 (64%) 0.60
No 55 (31%) 123 (69%)
Family history of cancer
Yes 18 (43%) 24 (57%) 0.07 0.37
No 45 (28%) 113 (72%)
aMixed race, Aboriginal and Torres Strait islander, Pacific islander, African.
bJewish, Johovah Witness, Buddhist, Scientology, Fundamental (unclassified), or Special (unclassified).
cMultivariate analysis ANOVA included religion, education, income, family history of cancer, knowledge of genetics, emotional disadvantage, insurance disadvantage
and employment disadvantage, and previous behavior in relation to Down syndrome testing in the preceding pregnancy.
well as alleged discrimination against asymptomatic employes on
the basis of information obtained from genetic test results or family
history (20). One of the cases involving request of pre-employment
genetic information pertained to that of a young woman with a
relevant family history, who was allegedly informed that a suc-
cessful job application in the public service would be conditional
upon negative genetic testing for familial adenomatous polyposis.
Further cases of alleged genetic-based employment discrimination
were identified against existing employes, with cases involving ter-
mination of employment or demotion of individuals with positive
genetic tests for familial early-onset alzheimer’s or Huntington’s
disease (20).
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Table 3 | Impact of genetic knowledge, attitudes toward carrier status, and previous decision-making on Down syndrome investigations on test
uptake.
Variables Accept test (N =63) Decline test (N =137) p-Value (univariate) p-Valueb (multivariate)
Knowledge of geneticsa
Median (IQR) 5 (3–8.5) 3 (1–8) 0.03 0.19
Attitudes to carrier status
Emotional disadvantage
No 37 (69%) 17 (31%) <0.0001 <0.0001
Uncertain 15 (22%) 52 (78%)
Yes 11 (14%) 66 (86%)
Missing data 0 2
Insurance disadvantage
No 40 (80%) 10 (20%) <0.0001 <0.0001
Uncertain 12 (15%) 67 (85%)
Yes 11 (16%) 59 (84%)
Missing data 1
Employment disadvantage
No 42 (52%) 38 (48%) <0.0001 <0.0001
Uncertain 11 (19%) 48 (81%)
Yes 10 (17%) 50 (83%)
Missing data 0 1
Decision on down syndrome testing
Underwent a test 60 (55%) 48 (45%) <0.0001 <0.0001
Declined testing 3 (3%) 89 (97%)
aRange 0–15: 0= low knowledge, no correct answers in test to 15=high knowledge, all answers correct in test.
bMultivariate analysis ANOVA included religion, education, income, family history of cancer, knowledge of genetics, emotional disadvantage, insurance disadvantage
and employment disadvantage, and previous behavior in relation to Down syndrome testing in the preceding pregnancy.
EMOTIONAL DISCRIMINATION
Conflicting results have emerged from the limited research eval-
uating concerns over emotional disadvantage and genetic testing
behavior. In some studies individuals reported heightened lev-
els of disease-related anxiety up to 18 months following receipt
of the test results for a hereditary cardiac condition (21) while
other studies reported only temporary mild increases in general
anxiety or depression (22,23). The inconsistencies may be attribut-
able to complexities in applying standardized testing for emotional
responses. For example, the adverse emotional responses reported
by individuals who underwent testing for a hereditary colorectal
cancer included feelings of guilt and injustice, fear of cancer when-
ever a new symptom arose, use of emotion regulation strategies
such as denial and immersion into work activities, difficulties com-
municating news to relatives, and uncertainty and worries about
the future (24). These emotional concerns are difficult to translate
using standard indices of distress and adjustment.
Interestingly, one study considered the impact of pre-existing
psychological vulnerability and reported evidence that the highest
levels of depressive symptoms occurred in participants with a high
baseline stress who subsequently declined test uptake (25).
PRIOR TEST BEHAVIOR
Uptake of the hypothetical genetic cancer test correlated with a
positive decision to uptake genetic testing for Down Syndrome
in the immediate preceding pregnancy. This might be accounted
for by consistency in the behavioral factors influencing a person
to uptake a test, and reflect internal behavioral paradigms or the
decision-maker’s values and beliefs. Inherently the test scenario
is different. One is a test on the unborn child and the other a
test of the proband themselves. The common link is the genetic
nature of the test. However, previous studies have identified a key
constituent in the decision-making process – the influence of the
decision-makers’ values and beliefs (26–29). This could account
for the correlation between the decision to uptake an initial ante-
natal screening test with that of a subsequent genetic screening test,
since it may be postulated that the decision-maker employs similar
guiding principles in the process of deciding upon test uptake.
PRIOR FAMILY HISTORY
This study did not report a prior family history of genetic dis-
ease or of cancer as being significant variables associated with test
uptake. There was a trend in univariate analysis for a family history
of cancer to be associated with an increased test uptake (p= 0.07).
This trend did not follow into multivariate analysis (p= 0.37).
However, other studies have reported family history to be a factor
in decision-making (2, 3).
STRENGTHS ANDWEAKNESSES
This study has a number of strengths and weaknesses.
Strengths are the diversity of the patient population in race, reli-
gion, educational level, and cultural experience. The high recruit-
ment rate and inclusion of non-English speaking participants are
also strengths.
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The study weaknesses are that recruitment came from a sin-
gle institution, the inability to internally validate the responses on
a second occasion and the inability to provide specific counsel-
ing about the possibility of screening and/or taking preventative
measures for any cancer susceptibility.
CONCLUSION
Despite the growing array of genetic tests available to identify vul-
nerability to certain disease states, our results suggest that when
individual’s perceive there is potential for misuse of genetic infor-
mation by employers upon which to base personnel decisions, or
a fear of potential adverse emotional outcomes, there is reluctance
to participate in genetic testing. A previous history of accepting
genetic testing predisposes to testing uptake. Further systematic
data is required to gage whether these concerns are founded and
whether existing legislative protection is adequate.
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